| Literature DB >> 32179810 |
Farah Tasnim1, Nisha Hari Singh1, Elijah Keng Foo Tan2,3, Jiangwa Xing1, Huan Li1, Sebastien Hissette1, Sravanthy Manesh4, Justina Fulwood4, Kapish Gupta2, Chan Way Ng3, Shuoyu Xu1, Jeffrey Hill4,5, Hanry Yu6,7,8,9.
Abstract
Hepatocyte spheroids are useful models for mimicking liver phenotypes in vitro because of their three-dimensionality. However, the lack of a biomaterial platform which allows the facile manipulation of spheroid cultures on a large scale severely limits their application in automated high-throughput drug safety testing. In addition, there is not yet a robust way of controlling spheroid size, homogeneity and integrity during extended culture. This work addresses these bottlenecks to the automation of hepatocyte spheroid culture by tethering 3D hepatocyte spheroids directly onto surface-modified polystyrene (PS) multi-well plates. However, polystyrene surfaces are inert toward functionalization, and this makes the uniform conjugation of bioactive ligands very challenging. Surface modification of polystyrene well plates is achieved herein using a three-step sequence, resulting in a homogeneous distribution of bioactive RGD and galactose ligands required for spheroid tethering and formation. Importantly, treatment of polystyrene tethered spheroids with vehicle and paradigm hepatotoxicant (chlorpromazine) treatment using an automated liquid handling platform shows low signal deviation, intact 3D spheroidal morphology and Z' values above 0.5, and hence confirming their amenability to high-throughput automation. Functional analyses performance (i.e. urea and albumin production, cytochrome P450 activity and induction studies) of the polystyrene tethered spheroids reveal significant improvements over hepatocytes cultured as collagen monolayers. This is the first demonstration of automated hepatotoxicant treatment on functional 3D hepatocyte spheroids tethered directly on polystyrene multi-well plates, and will serve as an important advancement in the application of 3D tethered spheroid models to high throughput drug screening.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32179810 PMCID: PMC7075904 DOI: 10.1038/s41598-020-61699-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Characterization of successful polymer grafting on polystyrene surface. (A) Schematic diagram of the procedure for surface modification of polystyrene (PS) surface to enable UV-induced graft copolymerisation of acrylic acid (AAc) monomer using a two-step UV treatment method and consecutive ligand conjugation onto the polyacrylic acid (pAAc) grafted PS surface (PS-pAAc). (B) XPS analysis to verify grafting of pAAc on PS surface in comparison to previously used PET films (lower panel) compared to their respective pristine surfaces (upper panel) (C) Grafting density of pAAc on PS (in comparison to PET) determined by a colorimetric method using Toluidine Blue O (TBO) staining as described previously[27] and water contact angle of PS-pAAc and PET-pAAc (in comparison to their respective pristine surfaces) measured by sessile drop method on a goniometer.
Stiffness and roughness of unmodified (pristine) and modified polyethylene terephthalate (PET) and polystyrene (PS) surfaces after polyacrylic acid grafting (pAAc) and bioligand conjugation (Gal/RGD/Gal: RGD Hybrid) determined by AFM analysis.
| Stiffness (MPa) | Mean Root Square Roughness (Ra)/nm | |||
|---|---|---|---|---|
| PET | PS | PET | PS | |
| Pristine | 646 | 750 | 1.46 | 2.89 |
| pAAc | 970 | 901 | 5.49 | 11.3 |
| Gal | 728 | 600 | 1.48 | 15.3 |
| RGD | 734 | 967 | 2.90 | 25.7 |
| Gal: RGD Hybrid | 639 | 511 | 2.53 | 31.4 |
Gal: galactose, RGD: Arg-Gly-Asp.
Summary of spheroid number, mean spheroid diameters and diameter dispersity calculated across three representative wells of tethered rat hepatocytes.
| Rat Hepatocytes | |||
|---|---|---|---|
| Total Spheroid Number | Number of Spheroids < 150 μm | Mean Diameter (μm) | |
| Donor A | 101 | 69 | 126.00 |
| Donor B | 96 | 61 | 126.43 |
| Donor C | 119 | 74 | 123.96 |
| Mean | |||
| Standard Deviation | |||
| Full width at 60% maximum of Gaussian curve (w) | 31.18 | 77.96 | 50.77 |
| Standard Deviation (w/2) | 15.59 | 38.98 | 25.38 |
| Mean Diameter (xc) | 126.00 | 126.43 | 123.96 |
| Polydispersity Coefficient (PD) | |||
Figure 2Adaptability of modified PS plates for automated platforms (A) Quantification of TBO staining across different wells and columns using absorbance measurement at 633 nm. (B) Homogeneity of cell attachment and viability across wells and columns with and without drug treatment determined using CellTiter-Glo 3D Cell Viability Assay five days after cell seeding. (C) Phase contrast images showing intact spheroids tethered to the plate after performing media change and dispensing the compounds using the Automated Liquid Handling Platform. Scale bar: 200 μm.
Figure 3Characterization of primary rat hepatocytes on modified PS plates in comparison to previously used PET films. (A) Phase contrast images showing spheroid formation by primary rat hepatocytes on PET and PS surfaces. Scale bar: 200 μm (B–D) Urea, albumin and CYP1A2 basal activity (determined by metabolite production upon metabolism of phenacetin) respectively in rat hepatocytes cultured on PET and PS surfaces for seven days. Error bars represent s.e.m, n = 3 (3 biological replicates; 3 technical replicates).
Summary of spheroid number, mean spheroid diameters and diameter dispersity calculated across multiple donors or batches of tethered human hepatocytes and compared to rat hepatocytes.
| Human Hepatocytes | ||||||
|---|---|---|---|---|---|---|
| Total Spheroid Number | Number of Spheroids < 150 μm | Mean Diameter (μm) | ||||
| Donor A | 63 | 40 | 133.57 | |||
| Donor B | 69 | 49 | 102.82 | |||
| Donor C | 65 | 52 | 118.69 | |||
| Mean | ||||||
| Standard Deviation | ||||||
| Donor | ||||||
| Full width at 60% maximum of Gaussian curve (w) | 31.18 | 77.96 | 50.77 | 102.90 | 45.42 | 53.68 |
| Standard Deviation (w/2) | 15.59 | 38.98 | 25.38 | 51.45 | 22.71 | 26.84 |
| Mean Spheroid Size (xc) | 126.00 | 126.43 | 123.96 | 133.57 | 102.82 | 118.69 |
| Polydispersity (PD) | ||||||
Figure 4Characterization of primary human hepatocytes (PHHs) on modified PS plates. (A) Phase contrast images showing spheroid formation by primary human hepatocytes on modified PS plates. Spheroid formation was observed within five days, while hepatocytes cultured on collagen (2D control) remained as a flat sheet. Scale bar: 250 μm (B) Albumin production by PHHs when cultured on collagen substrate and as tethered spheroids on modified PS plates (TS-PS) over one week. Error bars represent s.e.m, n = 3 (3 biological replicates from Donors A, B and C; 3 technical replicates were used for each donor). (C,D) Respective gene expression of CYP3A4 and CYP1A2 in PHHs (Donor A). Data are represented relative to GAPDH expression. Grey line indicates fold expression in TS-PS compared to collagen control. *p < 0.05; **p < 0.01 (E) Relative gene expression of Phase I and Phase II enzymes in PHHs in TS-PS compared to collagen control (Donor A). (F) Day 5 Basal activity of CYP1A2, CYP3A4 and CYP2B6 in PHHs in TS-PS compared to collagen control (Donor A). (G) Induction of CYP1A2, CYP3A4 and CYP2B6 in PHHs upon 48 hours treatment of CYP specific inducers (Donor A). Data are represented as fold change in induced activity compared to the basal activity. (C–G): Error bars represent s.e.m, n = 3 (3 technical replicates from Donor A). Data from Donor B and C are presented separately in Supplementary Figs. 3 and 4 due to lot-to-lot variability in PHHs CYP activity and induction.
Figure 5Treatment of TS-PS with four model hepatotoxicants. The cell viability of PHHs in TS- PS was assessed by Alamar Blue assay after exposure to different concentrations of Acetaminophen (A), Diclofenac (B), Chlorpromazine (C) and Troglitazone (D). Lines in each panel represent cell viability of PHHs at different concentrations of hepatotoxicants. Cell viability is expressed as a percentage of cells treated with solvent alone. Error bars represent s.e.m, n = 3 (3 biological replicates from Donors A, B and C; 3 technical replicates were used for each donor).
Figure 6Live cell imaging demonstrating the inhibition of tethering process of spheroids upon treatment with hepatotoxicants. Phase contrast images showing tethered spheroid formation on modified PS plates without (A) and with addition of hepatotoxicant, (10 mM APAP) (B). In untreated controls (upper panel), blebs, a typical feature of cell adhesion and migration was observed as early 2 hours upon initiation of live imaging. This was not observed when spheroids were treated with APAP (lower panel). Scale bar: 250 μm (C) Diameters of the spheroids upon treatment with different concentrations of APAP and untreated control (DMSO) were quantified at 4 different time points (2 hours, 8 hours, 16 hours and 24 hours upon drug addition). Higher density of spheroids with diameters >80 μm are observed in DMSO treated samples at 24 hours. This is not observed when the spheroids are treated with APAP, especially at concentrations >5 mM. Spheroids of diameter 90–120 μm at 24 hours were measured and expressed as percentage relative to 2 hours upon treatment with different concentrations of APAP (D) and troglitazone (E). Error bars represent s.e.m, n = 3 (3 biological replicates; 3 technical replicates).